[{"address1": "700 Saginaw Drive", "city": "Redwood City", "state": "CA", "zip": "94063", "country": "United States", "phone": "650 481 6801", "website": "https://www.revmed.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.", "fullTimeEmployees": 534, "companyOfficers": [{"maxAge": 1, "name": "Dr. Mark A. Goldsmith Ph.D.", "age": 62, "title": "CEO, President & Chairman", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 1115221, "exercisedValue": 2853049, "unexercisedValue": 32777390}, {"maxAge": 1, "name": "Mr. Jack  Anders", "age": 48, "title": "Chief Financial Officer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 665284, "exercisedValue": 1024663, "unexercisedValue": 1206837}, {"maxAge": 1, "name": "Ms. Margaret A. Horn J.D.", "age": 61, "title": "Chief Operating Officer", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 811075, "exercisedValue": 1681564, "unexercisedValue": 10104314}, {"maxAge": 1, "name": "Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.", "age": 63, "title": "President of Research & Development", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 812175, "exercisedValue": 0, "unexercisedValue": 7521715}, {"maxAge": 1, "name": "Ms. Xiaolin  Wang", "age": 53, "title": "Executive Vice President of Development", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 633737, "exercisedValue": 0, "unexercisedValue": 7283126}, {"maxAge": 1, "name": "Dr. Martin D. Burke M.D., Ph.D.", "title": "Co-Founder & Chairman of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael A. Fischbach Ph.D.", "age": 43, "title": "Academic Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kevan M. Shokat Ph.D.", "title": "Academic Co-Founder & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Walter  Reiher Ph.D.", "title": "Chief Information Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jan  Smith Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 38.58, "open": 38.19, "dayLow": 37.86, "dayHigh": 39.15, "regularMarketPreviousClose": 38.58, "regularMarketOpen": 38.19, "regularMarketDayLow": 37.86, "regularMarketDayHigh": 39.15, "payoutRatio": 0.0, "beta": 1.366, "forwardPE": -9.572839, "volume": 1075976, "regularMarketVolume": 1075976, "averageVolume": 1524507, "averageVolume10days": 1469320, "averageDailyVolume10Day": 1469320, "bid": 38.45, "ask": 39.02, "bidSize": 15, "askSize": 15, "marketCap": 7207846912, "fiftyTwoWeekLow": 29.17, "fiftyTwoWeekHigh": 62.4, "fiftyDayAverage": 37.8414, "twoHundredDayAverage": 44.25685, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 5054403584, "profitMargins": 0.0, "floatShares": 168212518, "sharesOutstanding": 185912992, "sharesShort": 16427758, "sharesShortPriorMonth": 16652995, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.0884, "heldPercentInsiders": 0.020060001, "heldPercentInstitutions": 1.08183, "shortRatio": 8.89, "shortPercentOfFloat": 0.0935, "impliedSharesOutstanding": 186930000, "bookValue": 12.185, "priceToBook": 3.1817808, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -600092992, "trailingEps": -3.58, "forwardEps": -4.05, "enterpriseToEbitda": -7.4, "52WeekChange": 0.044731855, "SandP52WeekChange": 0.07995045, "quoteType": "EQUITY", "currentPrice": 38.77, "targetHighPrice": 87.0, "targetLowPrice": 59.0, "targetMeanPrice": 72.33333, "targetMedianPrice": 71.5, "recommendationMean": 1.30769, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 12, "totalCash": 2289298944, "totalCashPerShare": 12.314, "ebitda": -682995968, "totalDebt": 135843008, "quickRatio": 13.966, "currentRatio": 14.2, "debtToEquity": 5.997, "returnOnAssets": -0.18656, "returnOnEquity": -0.29334, "grossProfits": -592225024, "freeCashflow": -347686496, "operatingCashflow": -557436032, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "RVMD", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 0.49247956, "regularMarketPrice": 38.77, "shortName": "Revolution Medicines, Inc.", "marketState": "CLOSED", "messageBoardId": "finmb_283775412", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "postMarketTime": 1745613692, "regularMarketTime": 1745611201, "exchange": "NMS", "postMarketChangePercent": 0.0, "postMarketPrice": 38.77, "postMarketChange": 0.0, "regularMarketChange": 0.18999863, "regularMarketDayRange": "37.86 - 39.15", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1524507, "fiftyTwoWeekLowChange": 9.6, "fiftyTwoWeekLowChangePercent": 0.32910526, "fiftyTwoWeekRange": "29.17 - 62.4", "fiftyTwoWeekHighChange": -23.630001, "fiftyTwoWeekHighChangePercent": -0.3786859, "fiftyTwoWeekChangePercent": 4.4731855, "earningsTimestamp": 1740603720, "earningsTimestampStart": 1746529140, "earningsTimestampEnd": 1747051200, "earningsCallTimestampStart": 1740605400, "earningsCallTimestampEnd": 1740605400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.58, "epsForward": -4.05, "epsCurrentYear": -4.48161, "priceEpsCurrentYear": -8.650909, "fiftyDayAverageChange": 0.9286003, "fiftyDayAverageChangePercent": 0.02453927, "twoHundredDayAverageChange": -5.4868507, "twoHundredDayAverageChangePercent": -0.12397743, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "longName": "Revolution Medicines, Inc.", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1581604200000, "displayName": "Revolution Medicines", "trailingPegRatio": null, "__fetch_time": "2025-04-26"}]